Hormonal
Activation of the nuclear receptor FXR by bile acids or synthetic agonists lowers plasma triglycerides and improves hyperglycemia in diabetic models.
While you cannot directly 'dose' bile acids safely without medical supervision, the paper suggests that modulating bile acid metabolism (e.g., via FXR agonists) is a promising pharmacological strategy for treating metabolic syndrome and type 2 diabetes. For now, maintaining a healthy gut microbiome supports normal bile acid cycling, which is linked to metabolic health.
activation of FXR by bile acids (BAs) or nonsteroidal synthetic FXR agonists lowers plasma triglycerides... activation of FXR improves hyperglycemia and dyslipidemia in vivo in diabetic mice.
Why this rating
Based on a comprehensive review of multiple animal models (FXR-deficient mice, diabetic mice) and molecular mechanisms.
Source
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Philippe Lefèbvre et al. · Physiological Reviews · 2009
DOI 10.1152/physrev.00010.2008
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →